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CAMPTOTHECIN INTERMEDIATES AND 
PRODRUGS AND METHODS OF 
PREPARATION THEREOF 
This application claims the bene?t of Us. Provisional 
Patent Application Ser. No. 60/469,754 ?led on May 12, 
2003. 
This invention Was made With Government support under 
5 
NIH Grant Number lR0lCA63653. The Government may 10 
have certain rights in this invention. 
TECHNICAL FIELD 
The present invention relates to novel intermediates and 
prodrugs of camptothecins. 
BACKGROUND OF THE INVENTION 
The anticancer agent camptothecin and related com 
20 
pounds (FIG. 1) are emerging as an important class of agents 25 
useful in the treatment of cancer. 
FIG. 1. Clinical candidates and FDA-approved analogs in 
the camptothecin family of antitumor agents 
2 
These agents display a unique mechanism of action: stabi 
liZation of the covalent binding of the enZyme topoi 
somerase I (topo I), an intranuclear enZyme that is overex 
pressed in a variety of tumor lines, to DNA. This drug/ 
enzyme/DNA complex leads to reversible, single strand 
nicks Which, according to the fork collision model, promote 
irreversible and lethal double strand DNA breaks during 
replication. 
The camptothecin class of anticancer agents have exhib 
ited unusual reactivity in vivo, both With respect to drug 
hydrolysis and blood protein interactions. These factors 
have hindered the pharmaceutical development and clinical 
implementation of camptothecins. In terms of hydrolysis, 
each of the camptothecins shoWn in FIG. 1 contains an 
ot-hydroxy-d-lactone pharmacophore. At physiological pH 
of 7 and above this functionality is reactive, readily con 
verting to the biologically inactive “ring opened” carboxy 
late form. Thus, as a result of the labile ot-hydroxy-d-lactone 
pharmacophore, an equilibrium is established betWeen tWo 
distinct drug species: 1) the biologically active lactone form 
Where the lactone ring remains closed; and 2) a biologically 
inactive carboxylate form generated upon the hydrolysis of 
the lactone ring of the parent drug. In this invention We 
describe novel intermediates and prodrugs of camptothecin 
and related analogs. 
Aqueous 
Solubility Compound R10 R1 R2 R3 
Soluble Topotecan/TPT H CH2NH(CH3)2 OH H 
" CDK602 H C2H5NHCH(CH3)2 H H 
Irinotecan/CPT-ll CZH5 H O 
< N N J'L O — 
GI-l472llC/GG-2ll H O 
\ 
— CH2— N N — CH3 
0/ 
Insoluble Calnptothecin H H H H 
" 9-AC H NH2 H H 
9-NC/Rubitecan H N02 H H 
SN-3 8 C2H5 H OH H 
DB-67 Si(CH3)2C(CH3)3 H OH H 
MDCPT H H O — 
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DETAILED DESCRIPTION OF THE 
INVENTION 
The invention includes camptothecin lactam intermedi 
ates With the following structure A: 
where R1 may be: a) hydrogen, a halogen atom, a branched 
or linear alkyl group, a branched or linear alkenyl group, 
a branched or linear alkynyl group, a cycloalkyl group, a 
cycloalkenyl group, an alkoxy group, an alkylamino 
group, a dialkylamino group, an alkylthiol group, a thiol 
group, a phenyl group, an amino group, a nitro group, a 
cyano group; b) a (CH2)YNR8R9 group, Wherein Y is an 
integer from lil0 and R8 and R9 are, independently, 
hydrogen, an alkyl group, an alkenyl group, an alkynyl 
group, an amine, an alkyl amine, a dialkyl amine, a 
hydroxy group, an alkoxy group, an acyl group, a car 
bamate; c) R8, R9 and the nitrogen to Which they are 
attached may be taken together to form a saturated or 
unsaturated three to ten membered heterocyclic ring 
Which may contain 0, S, NR1O where R10 is hydrogen, an 
alkyl group, an alkenyl group, an alkynyl group, an 
alkoxy group or a carbamate; d) R1 may be linked to R2 
as Rl(CH2)QR2 Wherein Q represents an integer 1e10, 
additionally this ring may contain one or more NH, O or 
S atoms in place of one or more 4CH2i groups; 
R2 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl group, 
a linear or branched alkynyl group, an amino group, an 
alkylamino group, a dialkylamino group, a nitro group, a 
3*l0 membered heterocyclic ring, a C3_ 10 cycloalkyl 
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl 
group, a thiol group, a cyano group; b) a (CH2)YNR8, R9 
group, Wherein Y is an integer from lil0 and R8 and R9 
are, independently, hydrogen, an alkyl group, an alkenyl 
group, an alkynyl group, an amine, an alkyl amine, a 
dialkyl amine, a hydroxy group, an alkoxy group, an acyl 
group, a carbamate; c.) R8, R9 and the nitrogen to Which 
they are attached may be taken together to form a satu 
rated or unsaturated three to ten membered heterocyclic 
ring; d) R2 may be linked to R3 as R2(CH2)GR3 Wherein 
G may be an integer from 1e10, additionally this ring may 
contain one or more NH, O or S atoms in place of one or 
more 4CH2i groups; 
R3 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl group, 
a linear or branched alkynyl group, an amino group, an 
alkylamino group, a dialkylamino group, a nitro group, a 
3*l0 membered heterocyclic ring, a C3_ 10 cycloalkyl 
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl 
group, a thiol group, a cyano group, a hydroxyl group; b) 
4 
a (CH2)YNR8R9 group, WhereinY is an integer from lil0 
and R8 and R9 are, independently, hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an amine, an 
alkyl amine, a dialkyl amine, a hydroxy group, an alkoxy 
5 group, an acyl group, a carbamate; c) R8, R9 and the 
nitrogen to Which they are attached may be taken together 
to form a saturated or unsaturated three to ten membered 
heterocyclic ring; d) R3 may be linked to R4 as R (CH2) 
GR4 Wherein G may be an integer from 1e10, additionally 
this ring may contain one or more NH, O or S atoms in 
place of one or more 4CH2i groups; 
R4 may be hydrogen, a halogen atom, a hydroxy group, an 
amino group, a methoxy group, an alkyl group, an alkynyl 
group or an alkenyl group; 
R5 may be hydrogen or ?uorine; 
R6 may be an alkyl group, an alkenyl group, an alkynyl 
group, or a benZyl group; 
R7 may be hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, a benZyl group, an alkoxy group, an 
aryloxy group, or an acyloxy group; and pharmaceutically 
acceptable salts thereof. 
The invention includes camptothecin ortho lactone inter 
mediates and prodrugs With the folloWing structure B: 
25 
30 
35 
40 where R1 may be: a) hydrogen, a halogen atom, a branched 
or linear alkyl group, a branched or linear alkenyl group, 
a branched or linear alkynyl group, a cycloalkyl group, a 
cycloalkenyl group, an alkoxy group, an alkylamino 
group, a dialkylamino group, an alkylthiol group, a thiol 
group, a phenyl group, an amino group, a nitro group, a 
cyano group; b) a (CH2)YNR8R9 group, Wherein Y is an 
integer from lil0 and R8 and R9 are, independently, 
hydrogen, an alkyl group, an alkenyl group, an alkynyl 
group, an amine, an alkyl amine, a dialkyl amine, a 
hydroxy group, an alkoxy group, an acyl group, a car 
bamate; c) R8, R9 and the nitrogen to Which they are 
attached may be taken together to form a saturated or 
unsaturated three to ten membered heterocyclic ring 
Which may contain 0, S, NR1O where R10 is hydrogen, an 
alkyl group, an alkenyl group, an alkynyl group, an 
alkoxy group or a carbamate; d) R1 may be linked to R2 
as Rl(CH2)QR2 Wherein Q represents an integer 1e10, 
additionally, this ring may contain one or more NH, O or 
S atoms in place of one or more iCHZi groups; 
60 R2 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl group, 
a linear or branched alkynyl group, an amino group, an 
alkylamino group, a dialkylamino group, a nitro group, a 
3*l0 membered heterocyclic ring, a C3_1O cycloalkyl 
group, a C3_1O cycloalkenyl group, a C8_1O cycloalkynyl 
group, a thiol group, a cyano group; b) a (CH2)YNR8R9 
group, Wherein Y is an integer from lil0 and R8 and R9 
50 
55 
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are, independently, hydrogen, an alkyl group, an alkenyl 
group, an alkynyl group, an amine, an alkyl amine, a 
dialkyl amine, a hydroxy group, an alkoxy group, an acyl 
group, a carbamate; c) R8, R9 and the nitrogen to Which 
they are attached may be taken together to form a satu 
rated or unsaturated three to ten membered heterocyclic 
ring; d) R2 may be linked to R3 as R2(CH2)GR3 Wherein 
G may be an integer from 1e10, additionally this ring may 
contain one or more NH, O or S atoms in place of one or 
more 4CH2i groups; 
R3 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl group, 
a linear or branched alkynyl group, an amino group, an 
alkylamino group, a dialkylamino group, a nitro group, a 
3*l0 membered heterocyclic ring, a C3_ 10 cycloalkyl 
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl 
group, a thiol group, a cyano group, a hydroxyl group; b) 
a (CH2)YNR8R9 group, WhereinY is an integer from lil0 
and R8 and R9 are, independently, hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an amine, an 
alkyl amine, a dialkyl amine, a hydroxy group, an alkoxy 
group, an acyl group, a carbamate c) R8, R9 and the 
nitrogen to Which they are attached may be taken together 
to form a saturated or unsaturated three to ten membered 
heterocyclic ring; d) R3 may be linked to R4 as R3 
(CH2)GR4 Wherein G may be an integer from 1e10, 
additionally this ring may contain one or more NH, O or 
S atoms in place of one or more 4CH2i groups; 
R4 may be hydrogen, a halogen atom, a hydroxy group, an 
amino group, a methoxy group, an alkyl group, an alkynyl 
group or an alkenyl group; 
R5 may be hydrogen or ?uorine; 
R6 may be an alkyl group, an alkenyl group, an alkynyl 
group, or a benZyl group; and 
R7 may be hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, a benZyl group, an alkoxy group, an 
aryloxy group, or an acyloxy group; and pharmaceutically 
acceptable salts thereof. 
The invention also includes camptothecin intermediates 
and prodrugs With the folloWing structure C: 
R1 
OR8 
on 
N w | 
R7 0 
where R1 may be: a) hydrogen, a halogen atom, a branched 
or linear alkyl group, a branched or linear alkenyl group, 
a branched or linear alkynyl group, a cycloalkyl group, a 
cycloalkenyl group, an alkoxy group, an alkylamino 
group, a dialkylamino group, an alkylthiol group, a thiol 
group, a phenyl group, an amino group, a nitro group, a 
cyano group; b) a (CH2)YNR8R9 group, Wherein Y is an 
integer from lil0 and R8 and R9 are, independently, 
hydrogen, an alkyl group, an alkenyl group, an alkynyl 
group, an amine, an alkyl amine, a dialkyl amine, a 
hydroxy group, an alkoxy group, an acyl group, a car 
bamate; or c) R8, R9 and the nitrogen to Which they are 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
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attached may be taken together to form a saturated or 
unsaturated three to ten membered heterocyclic ring 
Which may contain 0, S, NR1O where R10 is hydrogen, an 
alkyl group, an alkenyl group, an alkynyl group, an 
alkoxy group or a carbamate; d) R1 may be linked to R2 
as Rl(CH2)QR2 Wherein Q represents an integer 1e10, 
additionally this ring may contain one or more NH, O or 
S atoms in place of one or more iCHZi groups; 
R2 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl group, 
a linear or branched alkynyl group, an amino group, an 
alkylamino group, a dialkylamino group, a nitro group, a 
3*l0 membered heterocyclic ring, a C3_1O cycloalkyl 
group, a C3_1O cycloalkenyl group, a C8_1O cycloalkynyl 
group, a thiol group, a cyano group; b) a (CH2)YNR8R9 
group, Wherein Y is an integer from lil0 and R8 and R9 
are, independently, hydrogen, an alkyl group, an alkenyl 
group, an alkynyl group, an amine, an alkyl amine, a 
dialkyl amine, a hydroxy group, an alkoxy group, an acyl 
group, a carbamate; c) R8, R9 and the nitrogen to Which 
they are attached may be taken together to form a satu 
rated or unsaturated three to ten membered heterocyclic 
ring; d) R2 may be linked to R3 as R2(CH2)GR3 Wherein 
G may be an integer from 1e10, additionally this ring may 
contain one or more NH, O or S atoms in place of one or 
more 4CH2i groups; 
R3 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl group, 
a linear or branched alkynyl group, an amino group, an 
alkylamino group, a dialkylamino group, a nitro group, a 
3*l0 membered heterocyclic ring, a C3_1O cycloalkyl 
group, a C3_l0 cycloalkenyl group, a C8_l0 cycloalkynyl 
group, a thiol group, a cyano group, a hydroxyl group; b) 
a (CH2)YNR8R9 group, WhereinY is an integer from lil0 
and R8 and R9 are, independently, hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an amine, an 
alkyl amine, a dialkyl amine, a hydroxy group, an alkoxy 
group, an acyl group, a carbamate c) R8, R9 and the 
nitrogen to Which they are attached may be taken together 
to form a saturated or unsaturated three to ten membered 
heterocyclic ring; d) R3 may be linked to R4 as R3 
(CH2)GR4 Wherein G may be an integer from 1e10, 
additionally this ring may contain one or more NH, O or 
S atoms in place of one or more iCHZi groups; 
R4 may be hydrogen, a halogen atom, a hydroxy group, an 
amino group, a methoxy group, an alkyl group, an alkynyl 
group or an alkenyl group; 
R5 may be hydrogen or ?uorine; 
R6 may be an alkyl group, an alkenyl group, an alkynyl 
group, a benZyl group, an alkoxy group, an aryloxy group, 
or an acyloxy group; 
R7 may be hydrogen, an alkyl group, an alkenyl group, a 
benZyl group, an alkoxy group, an aryloxy group, or an 
acyloxy group; and 
R8 may be hydrogen, an alkyl group, or an alkenyl group; 
and pharmaceutically acceptable salts thereof. 
All compounds of the present invention including the 
[3-hydroxylactone group can exist in racemic form, enantio 
merically enriched from, and enantiomerically pure form. 
The formulas of such compounds as set forth herein cover 
and/or include each such form. 
The terms “alkyl”, “aryl” and other groups refer generally 
to both unsubstituted and substituted groups unless speci?ed 
to the contrary. Unless otherWise speci?ed, alkyl groups are 
hydrocarbon groups and are preferably C liC 1 5 (that is, 
having 1 to 15 carbon atoms) alkyl groups, and more 
preferably CFC1O alkyl groups, and can be branched or 
US 7,064,202 B1 
7 
unbranched, acyclic or cyclic. The above de?nition of an 
alkyl group and other de?nitions apply also When the group 
is a substituent on another group (for example, an alkyl 
group as a substituent of an alkylamino group or a dialky 
lamino group). The term “aryl” refers to phenyl or napthyl. 
As used herein, the terms “halogen” or “halo” refer to ?uoro, 
chloro, bromo and iodo. 
The term “alkoxy” refers to 4ORd, Wherein Rd is an alkyl 
group. The term “aryloxy” refers to ‘0R8, Wherein Re is an 
aryl group. The term acyl refers to iC(O)Rf. The term 
“alkenyl” refers to a straight or branched chain hydrocarbon 
group With at least one double bond, preferably With 2*15 
carbon atoms, and more preferably With 2*10 carbon atoms 
(for example, iCH=CHRg or 4CH2CH=CHRg). The 
term “alkynyl” refers to a straight or branched chain hydro 
carbon group With at least one triple bond, preferably With 
2*15 carbon atoms, and more preferably With 2*10 carbon 
atoms (for example, iCECRh or iCHzCsCRh). The terms 
“alkylene,” “alkenylene” and “alkynylene” refer to bivalent 
forms of alkyl, alkenyl and alkynyl groups, respectively. 
The groups set forth above, can be substituted With a Wide 
variety of substituents to synthesiZe homocamptothecin ana 
logs retaining activity. For example, alkyl groups may 
preferably be substituted With a group or groups including, 
but not limited to, a benZyl group, a phenyl group, an alkoxy 
group, a hydroxy group, an amino group (including, for 
example, free amino groups, alkylamino, dialkylamino 
groups and arylamino groups), an alkenyl group, an alkynyl 
group and an acyloxy group. In the case of amino groups 
(iNRaRb), R“ and Rh are preferably independently hydro 
gen, an acyl group, an alkyl group, or an aryl group. Acyl 
groups may preferably be substituted With (that is, Rf is) an 
alkyl group, a haloalkyl group (for example, a per?uoroalkyl 
group), an alkoxy group, an amino group and a hydroxy 
group. Alkynyl groups and alkenyl groups may preferably 
be substituted With (that is, Rg and Rh are preferably) a group 
or groups including, but not limited to, an alkyl group, an 
alkoxyalkyl group, an amino alkyl group and a benZyl 
group. 
The term “acyloxy” as used herein refers to the group 
iOC(O)Rd. 
The term “alkoxycarbonyloxy” as used herein refers to 
the group 4OC(O)ORd. 
The term “carbamoyloxy” as used herein refers to the 
group 4OC(O)NR“Rb. 
Amino and hydroxy groups may include protective 
groups as knoWn in the art. Preferred protective groups for 
amino groups include ter‘t-butyloxycarbonyl, formyl, acetyl, 
benZyl, p-methoxybenZyloxycarbonyl, trityl. Other suitable 
protecting groups as knoWn to those skilled in the art are 
disclosed in Greene, T., Wuts, P. G. M., Protective Groups 
in Organic Synthesis, Wiley (1991), the disclosure of Which 
is incorporated herein by reference. 
In general, R1, R2 and R3 are preferably not excessively 
bulky to maintain activity of the resultant camptothecin 
analog. Preferably, therefore, R1, R2 and R3 independently 
have a molecular Weight less than approximately 250. More 
preferably R1, R2 and R3 independently have a molecular 
Weight less than approximately 200. 
Some of the camptothecin analogs of the present inven 
tion can be prepared for pharmaceutical use as salts With 
inorganic acids such as, but not limited to, hydrochloride, 
hydrobromide, sulfate, phosphate, and nitrate. The camp 
tothecin analogs can also be prepared as salts With organic 
acids such as, but not limited to, acetate, tartrate, fumarate, 
succinate, citrate, methanesulfonate, p-toluenesulfonate, and 
stearate. Other acids can be used as intermediates in the 
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preparation of the compounds of the present invention and 
their pharmaceutically acceptable salts. 
For puri?cation, administration or other purposes, the 
E-ring (the lactone ring) may be opened With alkali metal 
such as, but not limited to, sodium hydroxide or calcium 
hydroxide, to form opened E-ring analogs of compounds of 
structures A, B and C. The intermediates thus obtained are 
more soluble in Water and may be puri?ed to produce, after 
treatment With an acid, a puri?ed form of the camptothecin 
analogs of the present invention. 
All the novel compounds of the present invention Whether 
in racemic, enantiomerically enriched or enantiomerically 
pure form display good biological activity While also pos 
sessing favorable characteristics for active loading into 
liposomal particle drug delivery systems of the micelle type 
disclosed and described in Us. Pat. Nos. 5,316,771; 5,552, 
156 and 5,736,156. Pre-made liposomes can be ef?ciently 
loaded With any of the novel compounds of structures A, B 
and C of this invention using pH gradients. 
In brief, in the active core loading process an amine 
containing agent is loaded into the particle. For example, a 
gradient created by ammonia gas diffusing out of the lipo 
some particle can result in diffusion or active loading of the 
compound/agent of the present invention inWard to the core 
of the particle. The chemical gradient across the membrane 
creates a driving force for the compound/ agent to replace the 
lost NH3 from the interior of the liposome. Once inside the 
acidic con?nes of the core, the compound/agent becomes 
protonated and remains Within the core, as its positive 
charge impedes retro-di?‘usion across the liposome bilayer. 
The protonated amine also prevents the occurrence of 
nucleophilic attack of the amine on the lactone carbonyl. As 
liposomes can be actively and/or passively targeted to the 
tumor, the liposome encapsulated compound/agent can be 
effectively concentrated at the tumor site, therby reducing 
exposure of the healthy host tissues to the cytotoxic agent 
yet enhancing exposure at the tumor target. 
The tumor targeted approach involving liposomal deliv 
ery of core loaded compound/agent addresses multiple clini 
cal issues. For example, reduced systemic toxicity can be 
achieved. Enhanced exposure at the tumor site in terms of 
relative amounts of drug reaching the tumor can also be 
achieved. Furthermore, enhanced exposure at the tumor site 
can be achieved in terms of prolonging the exposure of drug 
there. 
The present invention also provides a method of treating 
a patient, Which comprises administering a pharmaceutically 
effective amount of a compound of structures A, B and/or C 
or a pharmaceutically acceptable salt thereof. The com 
pound may, for example, be administered to a patient 
al?icted With cancer and/or leukemia. The compounds of the 
present invention may also act as antiviral (for example, 
anti-HIV) agents and antiparasitic agents. The pharmaceu 
tically effective amount or dosage is preferably betWeen 0.01 
to 80 mg of one of the compounds of structures A, B and/or 
C per kg of body Weight. More preferably, the pharmaceu 
tically effective amount or dosage is preferably betWeen 0.1 
to 40 mg of one of the compounds of structures A, B and/or 
C per kg of body Weight. In general, a pharmaceutically 
effective amount or dosage contains an amount of one of the 
compounds of structures A, B and/or C effective to display 
antileukemic and/or antitumor (anticancer) behavior. Phar 
maceutical compositions containing as an active ingredient 
of one of the compounds of structures A, B and/or C or a 
pharmaceutically acceptable salt thereof in association With 
a pharmaceutically acceptable carrier or diluent are also 
Within the scope of the present invention. 
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The compounds of the present invention may be admin 
istered as a pharmaceutical composition containing the 
compounds and a pharmaceutically acceptable carrier or 
diluent. The compounds can also be administered as their 
ring open salt forms, since relactoniZation to their active 
forms can occur in the body (especially at sites of reduced 
pH). The active material can also be mixed With other active 
materials Which do not impair the desired action and/or 
supplement the desired action. The compounds/active mate 
rials according to the present invention can be administered 
by any route, for example, orally, nasally, parenterally, 
intravenously, intradermally, subcutaneously, or topically, in 
liquid or solid form. 
For the purposes of parenteral therapeutic administration, 
the active ingredient may be incorporated into a solution or 
suspension. The solutions or suspensions may also include 
the folloWing components: a sterile diluent such as Water: 
for injection, suspensions of liposomal particles Whereby the 
particles contain stable, active drug Within the core of the 
particle in a pH controlled and protected environment or 
associated to the outside of the particle or any of the bilayers 
of the particle, saline solution, ?xed oils, polyethylene 
glycols, glycerine, propylene glycol or other synthetic sol 
vents; antibacterial agents such as benZyl alcohol or methyl 
parabens; antioxidants such as ascorbic acid or sodium 
bisul?te; chelating agents such as ethylenediaminetetraace 
tic acid; bulfers such as acetates, citrates or phosphates and 
agents for the adjustment of tonicity such as sodium chloride 
or dextrose. The parenteral preparation can be enclosed in 
ampoules, disposable syringes or multiple dose vials made 
of glass or plastic. 
Another mode of administration of the compounds of this 
invention is oral. Oral compositions Will generally include 
an inert diluent or an edible carrier. They may be enclosed 
in gelatin capsules or compressed into tablet. For the pur 
pose of oral therapeutic administration, the aforesaid com 
pounds may be incorporated With excipients and used in the 
form of tablets, troches, capsules, elixirs, suspensions, syr 
ups, Wafers, cheWing gums and the like. 
The tablets, pills, capsules and the like may contain the 
folloWing ingredients: a binder such as microcrystalline 
cellulose, gum tragacanth or gelatin; an excipient such as 
starch or lactose, a disintegrating agent such as alginic acid, 
Primogel, corn starch and the like; a lubricant such as 
magnesium stearate or Sterotes; a glidant such a colloidal 
silicon dioxide; and a sWeetening agent such as sucrose or 
saccharin or ?avoring agent such as peppermint, methyl 
salicylate, or orange ?avoring may be added. When the 
dosage unit is in the form of a capsule, it may contain, in 
addition to material of the above type, a liquid carrier such 
as a fatty oil. Other dosage unit forms may contain other 
various materials Which modify the physical form of the 
dosage unit, for example, as coatings. Thus tablets or pills 
may be coated With sugar, shellac, or other enteric coating 
agents. A syrup may contain, in addition to the active 
compounds, sucrose as a sWeetening agent and certain 
preservatives, dyes and coloring and ?avors. Materials used 
in preparing these various compositions should be pharma 
ceutically or veterinarally pure and non-toxic in the amount 
used. 
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The folloWing examples are presented to further illustrate 
the invention, but it is not to be considered as limited thereto. 
EXAMPLE 1 
Preparation of camptothecin and SN-38 20(S) 
(uu-aminoalkanoanic esters 
Camptothecin-20(S) (uu-aminoalkanoanic esters Were 
synthesiZed by a procedure described by Wall and Wani et 
al., With novel modi?cations. 
)ka/ NHBOC 
HO n 
n I 1, 2, 3 
EDCl, DMAP, cnzcl2 
O 
SN-38 uu-aminoalkanoanic esters, because of the presence 
of a l0-hydroxy group in addition to the 20(S)4OH, Were 
synthesiZed by a novel procedure. 
MOMCl, DIPEA 
—>
cnzcl2 
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-continued 
O 
O 
NHBOC 
HO n 
O n I 1, 2, 3 
U EDCl, DMAP, cnzcl2 
Brie?y, SN-38 (1 equiv) Was dissolved in anhydrous 
dichloromethane, and diisopropyl ethyl amine (DIPEA) (5 
equiv) Was added under nitrogen atmosphere. The reaction 
mixture Was stirred for 10 min at room temperature followed 
by the addition of methoxylmethylchloride (MOMCl) (5 
equiv). The resulting solution Was left stirring overnight. 
The reaction Was terminated. Then the reaction mixture Was 
diluted by dichloromethane and Washed several times With 
Water, dried (MgSO4), ?ltered, and concentrated. Puri?ca 
tion by chromatography on silica gel gave 10-MOM pro 
tected compound. 
1-Ethyl-3 -(3 -dimethylaminopropyl)carbodiimide (EDCI, 
3 equiv) Was sloWly added to a solution of 10-MOM 
protected compound (1 equiv), tert-butoxycarbonylamino 
acid (3equiv) and 4-(dimethylamino)pyridine (DMAP, 0.6 
equiv) and anhydrous dichloromethane, Which had been 
precooled to 00 C. The resulting solution Was alloWed to 
Warm to room temperature and stirred overnight. The 
organic fraction Was Washed With HCl (0.1 N) and Water and 
then extracted several times With CH2Cl2. Organic layers 
Were combined and dried With MgSO4, folloWed by ?ltra 
tion and concentration. Puri?cation of this residue by ?ash 
chromatography on silica gel gave chloromethyl methyl 
ether (MOM) and N-BOC protected prodrug. Deprotection 
of MOM and N-BOC groups Was achieved simultaneously 
by stirring MOM and N-BOC protected prodrug in dichlo 
romethane and tri?uoracetic acid for 30 minutes at room 
temperature, folloWed by concentration under high vacuum 
and recrystaliZation in methanol and ethyl ether. Purity of 
?nal products Was determined by HPLC and prodrug purity 
Was found to be greater than 98% pure. 
20 
25 
30 
35 
40 
45 
50 
55 
60 
65 
12 
EXAMPLE 2 
Synthesis of camptothecin-20-O-ester of 
N-methylglycine, mono (tri?uoroacetate) 
a. EDCl, DMAP, CHZCIZ, 
BOC OH 
\IiI/Y 
CH3 o 
O 
O O BOC 
/ W1“ 
0 CH3 
0 
o 0 CH3 
YN/ CF3COOH H 
o 
A solution of camptothecin (100 mg, 0.29 mmol), N-(tert 
butoxycarbonyl)metylyglycine (136 mg, 0.72 mmol) and 
DMAP(14 mg, 0.12 mmol) in 10 ml anhyd. dichlo 
romethane Was cooled to 00 C., folloWed by the addition of 
EDCI(110 mg, 0.57 mmol). The reaction mixture Was 
alloWed to come to room temperature and stirred overnight. 
The resulting solution Was Washed With HCl (5 ml, 0.1 N) 
and Water, then extracted With dichloromethane. The organic 
layer Was dried With MgSO4, then ?ltered and concentrated. 
Puri?cation by column chromatography on silica gel 
(CH2Cl24CH3COCH3, 9:1) gave solid (126 mg, 85%). 
lHNMR (400 MHZ, CDCl3): 1.00 (t, J:7.2, 3H), 1.44 (d, 
1:92, 9H), 20542.25 (m, 2H), 2.95 (s, 3H), 40341.32 (AB 
system, 2H), 5.30 (s, 2H), $3245.43 (A ofAB system, 1H), 
56845.73 (B of AB system, 1H), 7.19, 7.37 (ss, 1H), 
7.634769 (m, 1H), 7.8(%7.85 (m, 1H), 7.94 (t, 1:84, 1H), 
8.164825 (dd, 1:292, 1:84, 1H), 8.38 (d, 1:132, 1H). 
Camptothecin-20-O-ester of N-tert-butoxycarbonylmeth 
ylglycine (100 mg, 0.19 mmol) Were dissolved in dichlo 
romethane and tri?uoracetic acid, then stirred 30 min. at 
room temperature. The yelloW solution Was concentrated 
under high vacuum. RecrystaliZation by methanol and ethyl 
ether obtained solid 96 mg, yield 94%. lHNMR (400 MHZ, 
DMSO): 0.96 (t, J:7.23H), 2.1(%2.22 (m, 2H), 2.61 (s, 3H), 
4.284450 (AB system, 2H), 52745.38 (AB system, 2H), 
5.56 (s, 2H), 7.27 (s, 1H), 7.74 (t, 1:76, 1H), 7.88 (t, 1:76, 
1H), 8.144817 (d, 1:96, 2H), 8.73 (s, 1H), 9.15 (brs, 1H); 
l3CNMR (400 MHZ, DMSO): 7.56, 30.13, 32.53, 47.88, 
50.31, 66.39, 77.71, 95.30, 118.85, 127.84, 128.04, 128.67, 
128.78, 129.83, 130.60, 131.75, 144.58, 146.17, 147.90, 
152.33, 156.50, 166.10, 166.82 
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EXAMPLE 3 
Conversion of camptothecin and SN-38 20(S) u) 
aminoalkanoanic esters to lactam, ortho lactone and 
acetic acid Prodrugs 
The procedure involves placing in solution a 20-OR 
uu-aminoalkanoanic ester of camptothecin or SN-38, in 
Which R:CO[CH2]nNH2 and n:lI3. The basic amino group 
of the prodrug serves three roles. First, at pH ranges of 3 to 
5, it enhances aqueous solubility. Second, it enhances 
responsiveness to a transmembrane ammonium sulfate gra 
dient across the liposomal bilayer, thereby facilitating active 
loading of the agent into the liposomal aqueous core. Third, 
at a physiological pH of 7 or above (the pH to be encoun 
tered folloWing drug release at the tumor site), the nucleo 
philicity of the amine manifests itself and cycliZation to the 
C-21 carbonyl carbon occurs. This cycliZation triggers a 
rapid and convenient non-enZymatic decomposition process 
that releases active camptothecin. 
In contrast to l0-OR-CPT-20-OH compounds such as 
CPT-ll, Which are knoWn to exhibit hydrolysis-resistant 
carbamate bonds that require enZymatic cleavage, reversed 
phase high performance liquid chromatographic (RP-HPLC) 
studies of the stabilities of several l0-OH-CPT-20-OR and 
CPT-20-OR glycinate ester prodrugs (Where 
RICOCHZNH2) revealed extensive chemical (i.e. non-en 
Zymatic) decomposition in every case (CPT and SN-38 
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glycinate esters Were studied). Prodrug decomposition Was 
observed in phosphate buffered saline (PBS) at pH 7.4, as 
Well as in human plasma and blood. 
The presence of the amine functionality Was found to be 
essential for the prodrug decomposition. Whereas camptoth 
ecin-20(S)-glycinate l [1 uM, PBS (pH 7.4), 370 C.] under 
Went extensive decomposition (~90%) Within 3 hours, its 
corresponding aliphatic ester analog camptothecin-20(S) 
acetate (differing solely by the replacement of the amino 
group With a proton) demonstrated excellent stability in the 
above ?uids for days With negligible evidence of hydrolysis. 
Amine-containing esters of camptothecin With longer alkyl 
functionalities (RICOCHZCHZNHZ, 
R:COCH2CH2CH2NH2) also reacted under similar condi 
tions, albeit at a sloWer rate (half-lifes of 26.4 hr and 36.7 hr, 
respectively) than their glycinate counterparts. 
To better understand the mechanism of pro drug decom 
position, RP-HPLC coupled With electrospray ioniZation 
tandem mass spectrometry (ESl-MS/MS) and 13 C, 15N, and 
2D NMR experiments Were used to study the decomposition 
reaction of camptothecin-20(S)-glycinate. Camptothecin-20 
(S)-glycinate l decomposed to produce several products: the 
closed-ring lactone form of camptothecin 5, the ring-opened 
carboxylate form of camptothecin 6, and tWo novel decom 
position products 3 and 4 generated folloWing the formation 
of an unusual six membered morpholine 2,5-dione ring 2 (or 
lactam intermediate). 
Glycinate Ester of 
CPT (R1 I H, R3 I H); 
SN—38 (R1 I CH2CH3, R3 I OH) 
The lactam intermediate arose by intramolecular nucleo 
philic attack of the amino group on the lactone E-ring 
carbonyl carbon of camptothecin and is in fast equilibrium 
With structures 3 (Which We refer to as the ortho lactone) and 
US 7,064,202 B1 
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4. Ortho lactone 3 arose by a second intramolecular reaction 
Within the lactam intermediate and 3 exhibited the same 
mass as camptothecin-20(S)-glycinate ester but With a strik 
ingly different fragmentation pattern. 4 arose by a competi 
tive intermolecular reaction to the lactam intermediate and 
reacted to release both 5 and 6. HPLC-ESI-MS full scan 
shoWed the mass values for the protonated molecular (MH+) 
ions of camptothecin glycinate ester degradation products 
Were: 1 (406), 3 (406), 4 (424), 5 (349), 6 (389). 
MS/MS shoWed that CPT glycinate ester 1 and CPT ortho 
lactone 3 Were isomers With different fragmentation pattern. 
CPT glycinate fragmentation pattern [m/Z(%)] Was: 406 
(25%), 331 (100%), 303 (30%); CPT ortho lactone frag 
mentation pattern Was: 406 (100%), 388 (40%), 303 (20%). 
Likewise, N-substituted glycinate ester analogs of other 
camptothecins (1 11M, in PBS, pH 7.4), including SN-38, 
underWent extensive decomposition (~90%) Within 3 hours. 
HPLC data for each analog studied Was consistent With the 
generation of the novel decomposition products, along With 
the lactone and carboxylate forms of the parent drug. ESI 
MS/ MS analysis indicated that the proposed ortho lactone 3 
generated for N-methyl CPT glycinate ester displayed the 
same mass as the ester but With a different fragmentation 
pattern. HPLC-ESI-MS full scan shoWed the mass values for 
the protonated molecular (MH+) ions of N-methyl camp 
tothecin glycinate ester degradation products Were: 1 (420), 
3 (420), 4 (438), 5 (349), 6 (389). MS/MS shoWed that 
N-methyl CPT glycinate ester 1 and CPT N-methyl ortho 
lactone 3 Were isomers With different fragmentation pattern. 
N-methyl CPT glycinate fragmentation pattern [m/Z(%)] 
Was: 420 (86%), 331 (100%), 303 (30%); CPT N-methyl 
ortho lactone fragmentation pattern Was: 420 (100%), 402 
(50%), 303 (37%). As in the case for the camptothecin 
glycinate ester, the novel degradation products Were gener 
ated from the proposed lactam intermediate. Further evi 
dence for proposed degradation products 3 and 4 includes: 
(1) Glycine carbonyl 13 C isotopic labeling NMR experiment 
in PBS shoWing that this carbon exists as a tetrahedral 
carbon as in 3. (2) Glycine l5N isotopic labeling NMR 
experiments shoWing that 3 and 4 have amide bonds. (3) 2D 
NMR spectrum of isolated N-methyl camptothecin ortho 
lactone 3 
# 6C 6B Observed Coupling 
2 152.8 f 3JCH 11-5, 11-7, 11-14 
3 142.7 f 2JCH 11-14; 5JCH H-17b 
5 50.0 5.26(2H) 3JCH H-7 
6 129.8 f 2JCH H-5 
7 131.5 8.66(1H) 3JCH 115,119 
8 127.5 f i 
9 128.5 8.08(1H) JCH 11-7 
10 127.8 7.69(1H) JCH 11-12 
11 130.3 7.86(1H) JCH 11-9 
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-continued 
Atom DMSO ppm 
# 6C 6B Observed Coupling 
12 129.0 8.17(1H) 3JCH 11-10 
13 147.9 f 3JCH 117,119, 11 11 
14 100.4 7.26(1H) JCH H-17b 
15 150.6 f 3JCH H—19b,H-17a 
16 128.2 f 2JCH H-l7él, H-17b; 3JCH H-14 
17 57.4 4.83(1H, a), i 
5.03(111, b) 
18 7.9 0.92(311) 2JCH H-l9él, H-19b 
19 33.1 2.05(111, a), 2JCH 11-18 
2.35(111, b) 
20 82.0 i 2JCH H-l9él, H-19b; 3JCH 11-14, 11-1 
21 166.6 f 3JCH H-l9él, 11-26; 6JCH H-17b 
23 54.8 3.41(111, a), 3JCH H-26, OH 
3.71(111, b) 
24 107.1 f 2JCH H-23é1, H-23b, OH; 3JCH H-17 
H-17b; ‘*JCH H-26 
26 34.1 2.85(3H) 3JCH H-233. 
OH 4 8.06(1H) 4 
EXAMPLE 4 
Procedure for the Isolation of the ortho lactone 
from CPT-N-methyl glycinate 
Camptothecin N-methyl glycinate tri?uoroacetic acid salt 
Was dissolved in DMF, 1.2 eq. triethylamine Was then added 
and reaction stirred overnight at room temperature. Organic 
solvent Was removed and a yelloW precipitate Was rinsed 
With Water, ?ltered, and dried under vacuum. Yield: 98%. 
EXAMPLE 5 
Procedure for the Isolation of the ortho lactone 
from SN-38 methyl glycinate ester 
SN-38 N-methyl glycinate tri?uoroacetic acid salt Was 
dissolved in unhydrous DMF, 1.5 eq. triethylamine Was then 
added and reaction stirred overnight at room temperature. 
Organic solvent Was removed and residue Was rinsed With 
Water to remove salt, SN-38 N-methyl ortho lactone Was 
extracted With ethyl acetate. 
EXAMPLE 6 
Procedure for the Isolation of the ortho lactone 
from 9-NC-methyl glycinate ester 
9-Nitro Camptothecin N-methyl glycinate hydrocholoride 
Was dissolved in DMF, 1.5 eq. triethylamine Was then added 
and reaction stirred overnight at room temperature. Organic 
solvent Was removed and residue Was dried under vacuum. 
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EXAMPLE 7 
Procedure for the Isolation of the Ortho Lactone 
from 10,11-MDCPT-20-glycinate ester 
10,11-methylenedioxy Camptothecin N-methyl glycinate 
hydrocholoride Was in anhydrous dichlo 
romethane, 1.5 eq. triethylamine Was added and reaction 
stirred overnight at room temperature. Organic solvent Was 
removed and residue Was rinsed With Water and dried under 
vacuum. 
dissolved 
EXAMPLE 8 
LC/MS Condition for Elucidation of Degradation 
Products of Camptothecin-20(S)-Glycinate in 
Aqueous Solution 
The LC/MS system consisted of an HP 1100 HPLC 
equipped With a 50><1.0 mm id. (3 micron) Luna C18 
microbore column (Phenomex, Torrence, Calif). lsocratic 
separations Were preformed at 35 uL/min using 80% aceto 
nitrile and 20% 10 mM ammonium for'mate pH 5.5. Salts in 
the samples Were diverted from the mass spectrometer 
during the ?rst tWo minutes of each experiment. Electro 
spray mass spectra Were acquired on a Finnigan LCQ 
Classic (San Jose, Calif.) quadrupole ion trap mass spec 
trometer in the positive ion mode. Standard electrospray 
conditions Were used (spray voltage 4.5 kV, shealth gas ?oW 
rate 60 arb. units, and capillary temp. 2250 C.). Full scan 
mass spectra Were obtained over a range of 100 to 1000 m/Z. 
Typical tandem mass spectra parameters Were 3 m/Z isola 
tion Width, 35% normaliZed collision energy, qZ:0.25 and 
CID time of 30 ms. 
EXAMPLE 9 
Remote “active” loading of prodrug into premade small 
unilamellar vesicles, With diameters of 100 nm, Was carried 
out by using transmembrane ammonium sulfate gradients. 
Prodrug Was added to a liposomal suspension Where initially 
[(NH4)2SO4]CORE' [(NH4)2SO4]EXTERNAL; loading of the 
prodrug occurred as a result of base exchange (initiated by 
NH3 gas molecules departing the liposome). Whereas 
underivatiZed camptothecin and DB-67 localiZe predomi 
nantly in the bilayer compartment of the liposome, their 
20-OR prodrugs, Where R) CO[CH2]nNH 2 and n) 143, 
loaded With high ef?ciency (60 to 90%) into the core of 
liposomes at clinically relevant drug-to-lipid ratios (betWeen 
1:4 to 1:20). More importantly, these core-loaded liposomal 
formulations of camptothecin 4-aminobutanoate ester and 
DB-67 4-aminobutanoate ester exhibited markedly 
improved stabilities in Whole blood relative to their free 
forms. Whereas the decomposition of free prodrug in both 
cases Was extensive, liposomal entrapment prevented the 
degradation process from occurring, providing indirect evi 
dence that the prodrug was effectively retained Within the 
liposome for periods up to 40 h. These time periods are 
knoWn to be suf?cient for successful tumor-targeting to be 
achieved. 
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What is claimed: 
1. A compound With the formula: 
where R1 may be: a) hydrogen, a halogen atom, a 
branched or linear alkyl group, a branched or linear 
alkenyl group, a branched or linear alkynyl group, a 
cycloalkyl group, a cycloalkenyl group, an alkoxy 
group, an alkylamino group, a dialkylamino group, an 
alkylthiol group, a thiol group, a phenyl group, an 
amino group, a nitro group, a cyano group; b) a 
(CH2)YNR8R9 group, WhereinY is an integer from 1410 
and R8 and R9 are, independently, hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an amine, an 
alkyl amine, a dialkyl amine, a hydroxy group, an 
alkoxy group, an acyl group, a carbamate; 
R2 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl 
group, a linear or branched alkynyl group, an amino 
group, an alkylamino group, a dialkylamino group, a 
nitro group, a 3410 membered heterocyclic ring, a 
C3_1O cycloalkyl group, a C3_l0 cycloalkenyl group, a 
C8_1O cycloalkynyl group, a thiol group, a cyano group; 
b) a (CH2)YNR8 R9 group, WhereinY is an integer from 
1410 and R8 and R9 are, independently, hydrogen, an 
alkyl group, an alkenyl group, an alkynyl group, an 
amine, an alkyl amine, a dialkyl amine, a hydroxy 
group, an alkoxy group, an acyl group, a carbamate; 
R3 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl 
group, a linear or branched alkynyl group, an amino 
group, an alkylamino group, a dialkylamino group, a 
nitro group, a C3_1O cycloalkyl group, a C3_1O cycloalk 
enyl group, a C8_1O cycloalkynyl group, a thiol group, 
a cyano group, a hydroxyl group; b) a (CH2)YNR8R9 
group, WhereinY is an integer from 1410 and R8 and R9 
are, independently, hydrogen, an alkyl group, an alk 
enyl group, an alkynyl group, an amine, an alkyl amine, 
a dialkyl amine, a hydroxy group, an alkoxy group, an 
acyl group, a carbamate; 
R4 may be hydrogen, a halogen atom, a hydroxy group, an 
amino group, a methoxy group, an alkyl group, an 
alkynyl group or an alkenyl group; 
R5 may be hydrogen or ?uorine; 
R6 may be an alkyl group, an alkenyl group, an alkynyl 
group, or a benZyl group; 
R7 may be hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, a benZyl group, an alkoxy group, an 
aryloxy group, or an acyloxy group; and pharmaceuti 
cally acceptable salts thereof. 
2. 
US 7,064,202 B1 
19 
A compound With the formula: 
on 
N w | 
R7 0 
where R1 may be: a) hydrogen, a halogen atom, a 
branched or linear alkyl group, a branched or linear 
alkenyl group, a branched or linear alkynyl group, a 
cycloalkyl group, a cycloalkenyl group, an alkoxy 
group, an alkylamino group, a dialkylamino group, an 
alkylthiol group, a thiol group, a phenyl group, an 
amino group, a nitro group, a cyano group; b) a 
(CH2)YNR8R9 group, WhereinY is an integer from lil0 
and R8 and R9 are, independently, hydrogen, an alkyl 
group, an alkenyl group, an alkynyl group, an amine, an 
alkyl amine, a dialkyl amine, a hydroxy group, an 
alkoxy group, an acyl group, a carbamate; 
R2 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl 
group, a linear or branched alkynyl group, an amino 
group, an alkylamino group, a dialkylamino group, a 
nitro group, a 3*l0 membered heterocyclic ring, a 
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C3_1O cycloalkyl group, a C3_l0 cycloalkenyl group, a 
C87l0 cycloalkynyl group, a thiol group, a cyano group; 
b) a (CH2)YNR8R9 group, WhereinY is an integer from 
lil0 and R8 and R9 are, independently, hydrogen, an 
alkyl group, an alkenyl group, an alkynyl group, an 
amine, an alkyl amine, a dialkyl amine, a hydroxy 
group, an alkoxy group, an acyl group, a carbamate; 
R3 may be: a) hydrogen, a halogen atom, a linear or 
branched alkyl group, a linear or branched alkenyl 
group, a linear or branched alkynyl group, an amino 
group, an alkylamino group, a dialkylamino group, a 
nitro group, a 3*l0 membered heterocyclic ring, a 
C3_1O cycloalkyl group, a C3_l0 cycloalkenyl group, a 
C8_1O cycloalkynyl group, a thiol group, a cyano group, 
a hydroxyl group; b) a (CH2)YNR8R9 group, WhereinY 
is an integer from lil0 and R8 and R9 are, indepen 
dently, hydrogen, an alkyl group, an alkenyl group, an 
alkynyl group, an amine, an alkyl amine, a dialkyl 
amine, a hydroxy group, an alkoxy group, an acyl 
group, a carbamate; 
R4 may be hydrogen, a halogen atom, a hydroxy group, an 
amino group, a methoxy group, an alkyl group, an 
alkynyl group or an alkenyl group; 
R5 may be hydrogen or ?uorine; 
R6 may be an alkyl group, an alkenyl group, an alkynyl 
group, a benZyl group, an alkoxy group, an aryloxy 
group, or an acyloxy group; 
R7 may be hydrogen, an alkyl group, an alkenyl group, a 
benZyl group, an alkoxy group, an aryloxy group, or an 
acyloxy group; and 
R8 may be hydrogen, an alkyl group, or an alkenyl group; 
and 
pharmaceutically acceptable salts thereof. 
* * * * * 
